CTRI/2023/06/053723尚未招募Unknown
Efficacy of Dapagliflozin vs Saroglitazar on hepatic steatosis & fibrosis in patients of type 2 diabetes mellitus with non-alcoholic fatty liver disease: A pilot randomised controlled trial.
Dr Bijay Ketan Das0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All patients meeting the diagnostic criteria for type 2 diabetes mellitus with non-alcoholic fatty liver disease
排除标准
- •Patients with HbA1c > 9%
- •Patients with prior treatment with pioglitazone, saroglitazar or dapaglifzolin , VIT E, UDCA and obeticholic acid or agents known to induce steatosis (like valproate, amiodarone, oc pills or methotrexate) in the Past 6 months.
研究者
相似试验
招募中
3 期
Safety and efficacy of Dapagliflozin and sitagliptin in elderly uncontrolled type 2 diabetes mellitus patientsCTRI/2023/06/053833Dr Mukku Venkata Pratap Reddy
已完成
不适用
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trialtype 2 diabetes mellitus, NAFLD, NASHJPRN-UMIN000030548Saitama Medical University Hospital100
尚未招募
4 期
Comparison of Dapagliflozin and Pioglitazone for Non-Alcoholic Fatty Liver Disease in Type 2 DiabetesCTRI/2024/07/071087Babra
进行中（未招募）
1 期
Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolusinsulin treatment (BBIT) regimen to a basal supported oral therapy(BOT) in patients with Type 2 Diabetes – a randomised double-blindedstudy – a randomised double-blinded studyEUCTR2015-005740-34-DEniversitätsklinikum Tübingen4
招募中
3 期
Effects of Dapagliflozin and Empagliflozin in Myocardial DysfunctioHeart failureIRCT20111206008307N45Tabriz University of Medical Sciences75